ProCE Banner Activity


Anticipating Advances in CAR T-Cell Therapies in Myeloma: Expert Discussion and Case Exploration


Watch this on-demand webcast featuring expert presentations and discussion on the latest developments in CAR T-cells for multiple myeloma, including new data and care for patients experiencing long-term toxicities.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: April 03, 2023



Amrita Krishnan

Amrita Krishnan, MD, FACP

Judy Bernard Briskin Center for Myeloma
Executive Director
Hematology City of Hope Irvine
Duarte, California

Nikhil Munshi

Nikhil Munshi, MD

Professor of Medicine
Harvard Medical School
Kraft Family Chair and Director for Basic and Correlative Sciences
Associate Director, Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with multiple myeloma who are likely to benefit from CAR T-cell therapy or are eligible for clinical trial enrollment

  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with multiple myeloma

  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools

  • Implement strategies to educate patients eligible for this treatment about the potential for these complications


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: Adaptive, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Regeneron, Sanofi, Sutro.

Nikhil Munshi, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, DCT, GlaxoSmithKline, Janssen, Legend Biotech, Novartis, Oncopep, Pfizer, Takeda; other (founder and/or stock options): DCT, Oncopep.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 03, 2023, through :

 1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. Study the educational activity online or printed out.

4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

Joint Accreditation



In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.